



PATENT  
Customer No. 22,852  
Attorney Docket No. 02356.0087-00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re Application of:

Yosser BEN ACHOUR et al.

Application No.: 10/733,232

Filed: December 12, 2003

For: GENE ASSOCIATED WITH  
LEISHMANIA PARASITE  
VIRULENCE

)  
)  
) Group Art Unit: 1645  
)  
) Examiner: Jana A. Hines  
)  
) Confirmation No.: 4579  
)  
)  
)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(c), applicant brings to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed after the events recited in Section 1.97(b) but, to the undersigned's knowledge, before the mailing date of either a Final action, Quayle action, or a Notice of Allowance. Under the provisions of 37 C.F.R. § 1.97(c), this Information Disclosure Statement is accompanied by a fee of \$180.00 as specified by Section 1.17(p).

Copies of the listed foreign and non-patent literature documents are attached. Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

05/08/2006 SZEWDIE1 00000021 10733232

03 FC:1006

100.00 DP

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claims in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: May 5, 2006

By: Mary B. Rucker  
Mary B. Rucker  
Reg. No. 56,992  
Tel.: (404) 653-6558  
Fax: (404) 653-6444  
mary.rucker@finnegan.com

IDS Form PTO/SB/08: Substitute for form 1449A/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)			Application Number	10/733,232	
			Filing Date	December 12, 2003	
			First Named Inventor	Yosser BEN ACHOUR et al.	
			Art Unit	1645	
			Examiner Name	Jana A. Hines	
			Attorney Docket Number	02356.0087-00000	
Sheet	1	of	2		

U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
		CA 2105538	04-03-1995	McGill University		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
		PADILLA et al.; "Isolation of a Unique Protein-Disulfide Isomerase Gene from <i>Leishmania donovani</i> ," Science Forum Poster Abstract, (2001).	
		MANDAL et al.; "The Plasma-Membrane Ca <sup>2+</sup> -ATPase of <i>Leishmania donovani</i> is an extrusion pump for Ca <sup>2+</sup> ," Biochem. J. Vol. 322, No. 1, pages 251-257, (1997).	
		CLIVE and GREENE; "Association of Protein Disulfide Isomerase Activity and the Induction of Contact Inhibition," Experimental Cell Research, Vol. 214, No. 1, pages 139-144, (1994).	
		ABDELHAK et al.; "Recombinant BCG expressing the Leishmania Surface Antigen Gp63 Induces Protective Immunity Against <i>Leishmania major</i> infection in BALB/c mice," Microbiology, Vol. 141, pages 1585-1592, (1995).	
		LYLES and GILBERT; "Catalysis of the Oxidative Folding of Ribonuclease A by Protein Disulfide Isomerase: Dependence on the Rate of the Composition of the Redox Buffer," Biochemistry, Vol. 30, No. 3, pages 613-619, (1991).	
		MOU et al.; "The Selective Inhibition of $\beta_1$ AND $\beta_7$ Integrin-Mediated Lymphocyte Adhesion by Bacitracin," The Journal of Immunology, Vol. 161, No. 11, pages 6323-6329, (1998).	
		HEARD et al.; " <i>Leishmania mexicana amazonensis</i> : Differential Display Analysis and Cloning of mRNAs from Attenuated and Infective Forms," J. Euk. Microbiol., Vol. 43, No. 5, pages 409-415, (1996).	
		YU et al.; "Key Role for DsbA in Cell-to-Cell Spread of <i>Shigella flexneri</i> , Permitting Secretion of Ipa Proteins into Interepithelial Protrusions," Infection and Immunity, Vol. 68, No. 11, pages 6449-6456, (2000).	

Sheet

2

of

2

## Application Number

10/733,232

**Filing Date**

December 12, 2003

*First Named Inventor*

Yosser BEN ACHOUR et al.

*Art Unit*

1645

**Examiner Name**

**Jana A. Hines**

Attorney Docket Number

02356.0087-00000

Examiner  
InitialsCite  
No.<sup>1</sup>

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

Translation<sup>8</sup>

KÉBAIER, et al.; "Heterogeneity of Wild *Leishmania major* Isolates in Experimental Murine Pathogenicity and Specific Immune Response," *Infection and Immunity*, Vol. 69, No. 8, pages 4906-4915, (2001).

MURPHY, et al.; "Leishmania major Friedline Assembled Shotgun Reads from Chromosome 36;" EMBL/GenBank/DDBJ database; Accession AL499624; Submitted May 18, 2001.

NORRISH, et al.; "LmFrAm0479 *Leishmania major* Amastigote Full Length cDNA Library *Leishmania major* cDNA Clone Q52 5', mRNA Sequence;" Accession AA680895; December 5, 1997.

LOUZIR; "Novel Gene Associated with Leishmania Parasite Virulence: Therapeutic and Vaccine Applications;" Pasteur Licensing Opportunity;  
url:[www.pasteur.fr/applications/dri/English/DI/00.80.html](http://www.pasteur.fr/applications/dri/English/DI/00.80.html).

ROVAI, et al.; "Recurrent Polymorphisms in Small Chromosomes of *Leishmania tarentolae* After Nutrient Stress or Subcloning;" Mol. Biochem. Parasitol., Vol. 50, No. 1, pages 115-125; (1992).

Examiner  
Signature

Date  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.